Arcus Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
RCUS New York 8731 https://arcusbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arcus Biosciences Inc

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma - Oct 2nd, 2024 8:05 pm
Arcus Biosciences Announces New Employment Inducement Grants - Sep 24th, 2024 8:35 pm
Arcus Biosciences obtains loan facility with Hercules Capital worth $250m - Aug 28th, 2024 6:33 pm
Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital - Aug 27th, 2024 8:05 pm
Arcus Biosciences to Participate in Two Upcoming Investor Conferences - Aug 21st, 2024 8:05 pm
Nuntius partners with Taiho to develop mRNA cancer therapies - Aug 16th, 2024 8:52 am
Arcus Biosciences Second Quarter 2024 Earnings: Beats Expectations - Aug 10th, 2024 12:14 pm
We're Not Very Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Rate - Aug 10th, 2024 12:13 pm
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates - Aug 8th, 2024 10:15 pm
Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update - Aug 8th, 2024 8:05 pm
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates - Aug 7th, 2024 9:15 pm
Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Aug 5th, 2024 2:00 pm
Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Aug 1st, 2024 2:01 pm
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors - Aug 1st, 2024 12:00 pm
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update - Jul 25th, 2024 8:05 pm
Taiho exercises option for Arcus Biosciences’ quemliclustat in Asia - Jul 9th, 2024 10:32 am
Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia - Jul 8th, 2024 10:00 pm
Arcus Completes Enrollment in Phase 3 Trial of Domvanalimab-Containing Regimen for Stomach Cancer - Jun 10th, 2024 3:15 pm
Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers - Jun 10th, 2024 12:30 pm
Is The Options Market Predicting a Spike In Arcus Biosciences (RCUS) Stock? - Jun 7th, 2024 2:55 pm